Interaction effect in bladder cancer between N-acetyltransferase 2 genotype and alcohol drinking

Urologia Internationalis

Volumn 75, Issue 4, 2005, Pages 360-364

  Lu, Chih Ming ^a,d   Chung, Meng Chu ^c   Huang, Chung Hsiung ^a,b   Ko, Ying Chin ^a,c  

^a KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^c NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^d BUDDHIST TZU CHI GENERAL HOSPITAL   (Taiwan)

Author keywords

Acetylation; Alcohol drinking; Bladder cancer; Nat2 genotype

Indexed keywords

ALCOHOL; ARYLAMINE ACETYLTRANSFERASE; DNA;

ADULT; AGED; ARTICLE; BLACKFOOT DISEASE; BLADDER CANCER; BLOOD CELL; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER RISK; CONFIDENCE INTERVAL; CONTROLLED STUDY; DNA EXTRACTION; DRINKING BEHAVIOR; ENDEMIC DISEASE; FEMALE; GENOTYPE; HOSPITAL; HUMAN; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; QUESTIONNAIRE; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; TAIWAN;

AGED; ALCOHOL DRINKING; ARYLAMINE N-ACETYLTRANSFERASE; DNA, NEOPLASM; FEMALE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; RISK FACTORS; URINARY BLADDER NEOPLASMS;

EID: 28644448219     PISSN: 00421138     EISSN: None     Source Type: Journal    
DOI: 10.1159/000089175     Document Type: Article

References (29)

1. Chen CJ, Chuang YC, You SL, Lin TM, Wu HY: A retrospective study on malignant neoplasms of bladder, lung and liver in blackfoot disease endemic area in Taiwan. Br J Cancer 1986;53:399-405.
2. Tsai SM, Wang TN, Ko YC: Mortality for certain diseases in areas with high levels of arsenic in drinking water. Arch Environ Health 1999;54:186-193.
3. Silverman DT, Morrison AS, Devesa SS: Bladder cancer; in Schottenfeld D, Fraumeni JFJ (eds): Cancer Epidemiology and Prevention. New York, Oxford University Press, 1996, pp 1156-1179.
4. Lower GMJ, Bryan GT: Etiology and carcinogenesis: natural system approaches to causality and control; in Javadpour N (ed): Principles and Management of Urologic Cancer. Baltimore, Williams & Wilkins, 1979, pp 29-53.
5. Lower GM Jr, Nilsson T, Nelson CE, Wolf H, Gamsky TE, Bryan GT: N-acetyltransferase phenotype and risk in urinary bladder cancer: approaches in molecular epidemiology. Preliminary results in Sweden and Denmark. Environ Health Perspect 1979;29:71-79.
6. 450 enzymes as modulators of bladder cancer risk. Cancer Res 1996;56:3915-3925.
7. Risch A, Wallace DM, Bathers S, Sim E: Slow N-acetylation genotype is a susceptibility factor in occupational and smoking-related bladder cancer. Hum Mol Genet 1995;4:231-236.
8. Vatsis KP, Weber WW, Bell DA, Dupret JM, Evans DA, Grant DM, Hein DW, Lin HJ, Meyer UA, Relling MV, Si E, Suzuki T, Tamazoe Y: Nomenclature for N-acetyltransferases. Pharmacogenetics 1995;5:1-17.
9. Fishbein L: Overview of some aspects of occurrence, formation and analysis of nitrosamines. Sci Total Environ 1979;13:157-188.
10. Morgan R, Jain M: Bladder cancer: smoking, beverages and artificial sweeteners. Can Med Assoc J 1974;111:1067-1070.
11. Michaud D, Spiegelman D, Clinton S, Rimm E, Curhan G, Willett W, Giovannucci E: Fluid intake and the risk of bladder cancer in men. N Engl J Med 1999;340:1390-1397.
12. Ko YC, Huang YL, Lee CH, Chen MJ, Lin LM, Tsai CC: Betel quid chewing, cigarette smoking and alcohol consumption related to oral cancer in Taiwan. J Oral Pathol Med 1995;24:450-453.
13. Chang MJ, Ko CY, Lin RF, Hsieh LL: Biological monitoring of environment exposure to safrole and the Taiwanese betel quid chewing. Arch Environ Contam Toxicol 2002;43:432-437.
14. Cartwright RA, Glashan RW, Rogers HJ, Ahmad RA, Barham-Hall D, Higgins E, Kahn MA: Role of N-acetyltransferase phenotypes in bladder carcinogenesis: a pharmacogenetic epidemiological approach to bladder cancer. Lancet 1982;ii:842-845.
15. Wolf H, Lower GM Jr, Bryan GT: Role of N-acetyltransferase phenotype in human susceptibility to bladder carcinogenic arylamines. Scand J Urol Nephrol 1980;14:161-165.
16. Mommsen S, Barfod NM, Aagaard J: N-acetyltransferase phenotypes in the urinary bladder carcinogenesis of a low-risk population. Carcinogenesis 1985;6:199-201.
17. Hanke J, Krajewska B: Acetylation phenotypes and bladder cancer. J Occup Med 1990;32:917-918.
18. Ladero JM, Kwok CK, Jara C, et al: Hepatic acetylator phenotype in bladder cancer patients. Ann Clin Res 1985;17:96-99.
19. Evans DAP, Eze LC, Whibley EJ: The association of the slow acetylator phenotype with bladder cancer. J Med Genet 1983;20:330-333.
20. Miller ME, Cosgriff JM: Acetylator phenotype in human bladder cancer. J Urol 1983;130:65-66.
21. Woodhouse KW, Adams PC, Clothier A, et al: N-acetyltransferase phenotype in bladder cancer. Hum Toxicol 1982;1:443-445.
22. Roots I, Drakoulis N, Brockmoller, J: Polymorphic enzymes and cancer risk: concepts, methodology and data review; in Pharmacogenetics of Drug Metabolism. New York, Pergamon Press, 1992, pp 815-841.
23. Hanssen HP, Agarwal DP, Goedde HW, Bucher H, Huland H, Brachmann W, Ovenbeck R: Association of N-acetyltransferase polymorphism and environmental factors with bladder carcinogenesis. Study in a north German population. Eur Urol 1985;11:263-266.
24. 4501A2 and N-acetyltransferases 1 and 2. Carcinogenesis 2003;24:483-489.
25. Bell DA, Taylor JA, Butler MA, Stephens E, Wiest J, Brubaker L, Kadlubar FF, Lucier GW: Genotype/phenotype discordance for human arylamine N-acetyltransferase (NAT2) reveals a new slow-acetylator allele common in African-Americans. Carcinogenesis 1993; 14:1689-1692.
26. Lin HJ, Han CY, Lin BK, Hardyt S: Slow acetylator mutations in the human polymorphic N-acetyltransferase gene in 786 Asians, Blacks, Hispanics, and Whites: application to metabolic epidemiology. Am J Hum Genet 1993;52:827-834.
27. Hsieh FI, Pu YS, Chern HD, Hsu LI, Chiou HY, Chen CJ: Genetic polymorphisms of N-acetyltransferase 1 and 2 and risk of cigarette smoking-related bladder cancer. Br J Cancer 1999;81:537-541.
28. Golka K, Prior V, Blaszkewicz M, Bolt HM: The enhanced bladder cancer susceptibility of NAT2 slow acetylators towards aromatic amines: a review considering ethnic differences. Toxicol Lett 2002;128:229-241.
29. Vineis P, Pirastu R: Aromatic amines and cancer. Cancer Causes Control 1997;8:346-355.